deltatrials
Completed PHASE2 NCT01314274

Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia

Sponsor: Medical University of Vienna

Conditions Epistaxis HHT Morbus Osler
Interventions Bevacizumab NaCl
Updated 5 times since 2017 Last updated: Aug 8, 2013 Started: Mar 31, 2011 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

A PHASE2 clinical study on Epistaxis and HHT, this trial is completed. The trial is conducted by Medical University of Vienna and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medical University of Vienna
Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Vienna, Austria